Treating Residual Disease in Upper GI Cancers Following FLOT Treatment

Immunotherapy combinations and targeted therapy options may help bridge clinical gaps in early-stage, locally advanced, and metastatic gastroesophageal adenocarcinomas.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Robot-assisted minimally invasive esophagectomies with anastomotic technique were completed without complications or mortality in a majority of patients.

Kelley A. Rone, DNP, RN, AGNP-c, provides perspective on approaching end-of-life conversations with patients with GI cancers.

A phase 2 study found that treatment with tumor-infiltrating lymphocytes elicited a partial response rate of 15.1% in patients with gastrointestinal cancers.

The FDA approved nivolumab with ipilimumab in adult and pediatric patients with CRC based on data from the phase 3 CHECKMATE-8HW trial.